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EDITORIAL
The virtues of observational medicine. Lessons from
the French Acute ST-elevation and non-ST-elevation
Myocardial Infarction (FAST-MI) registry
Les vertus de la médecine d’observation. Les apports du registre French
Registry on Acute ST-Elevation and non-ST-Elevation Myocardial Infarction
(FAST-MI)KEYWORDS
Myocardial infarction;
Registry;
Registries have become extremely fashionable in cardiology: a PubMed search with the
terms ‘‘acute myocardial infarction’’ and ‘‘registry’’ retrieved only 18 articles in 1995,
compared with 112 in 2010. One may therefore wonder why such a sudden interest in what
is only, after all, observational medicine.Cohort
MOTS CLÉS
Infarctus du
myocarde ;
Registre ;
Cohorte
To answer this question, one needs to determine what registries can (and cannot) bring
to clinicians. To this purpose, we will describe the experience from the French registries
in acute myocardial infarction (AMI), and particularly the French registry on Acute ST-
elevation and non-ST-elevation Myocardial Infarction (FAST-MI) [1].
The ﬁrst level of information brought by registries consists of an epidemiological
description of disease characteristics, management and outcomes. The FAST-MI registry
included patients admitted within 48 hours of symptom onset over a 1-month period at the
end of 2005, in centres participating on a voluntary basis throughout France [1]. FAST-MI
had been preceded by two nationwide registries based on a similar methodology—USIK 1995
[2] and USIC 2000 [3]. These three registries had the participation of 60—80% of French
institutions taking care of patients with AMI, and provided a unique opportunity to monitor
the characteristics and management of patients admitted to hospital for AMI in France.
In terms of the population description, probably the two most striking changes over the
10-year period, from 1995 to 2005, were the increased proportion of younger women (≤
50 years) among patients with ST-elevation myocardial infarction (STEMI), from 3.7% in
1995 to 11.2% in 2005 (Fig. 1), and the striking progression of body mass index (BMI), with
a 50% increase in the prevalence of obesity in patients admitted with AMI, from 14 to
21%. Although the second observation was expected because of the constant increase in
BMI in the general population, the ﬁrst came as much more of a surprise, and therefore
should generate questions and probably also speciﬁc measures in terms of public health
information, targeted to a public of younger women.
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statins and the occurrence of atrial ﬁbrillation at the acute
stage, suggesting a protective effect of these medications
vis-à-vis the development of acute episodes of atrial ﬁbril-
lation [7]. We also investigated the outcomes of diabetic44
Registries also interact with the guidelines from learned
ocieties in a two-way process. First, registries can deter-
ine whether the guidelines are actually applied in the ‘real
orld’ and can help to promote their application in clini-
al practice. For instance, in France, the use of reperfusion
herapy in STEMI patients has increased from 49% in 1995
o 63% in 2005, and this increase coincides with a reduction
n early mortality (decline in 5-day mortality from 8.6% in
995 to 6.4% in 2000 to 4.1% in 2005). Likewise, the prescrip-
ion of recommended medications at hospital discharge has
ncreased to levels that can now be considered rather ade-
uate, although some efforts to improve these rates remain
ecessary (96% for antiplatelet agents, 84% for statins, 69%
or angiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers, and 78% for beta-blockers). But registries
an also verify that recommendations issued from guidelines
re actually applicable. The 2003 guidelines on the man-
gement of STEMI of the European Society of Cardiology
ecommended that primary percutaneous coronary inter-
ention (PCI) be used if the time-to-balloon was expected
o be < 90min [4]. In FAST-MI, however, as in numerous other
egistries, the median time from ﬁrst call to reperfusion was
uch longer : 170min, and it was still 120min (interquar-
ile range 90, 170min) in the patients who had called the
AMU—Services d’Aide Médicale Urgente—directly, meaning
hat three of four patients treated with primary PCI for
TEMI were outside the recommended timeframe. The 2003
uidelines therefore appeared unrealistic ; the 2008 guide-
ine revision took into account this fact and recommended a
ime-to-balloon of < 120min (the 90-min goal remaining for
hose patients seen very early) [5].
Registries can also contribute signiﬁcantly to scientiﬁc
nowledge, and they can be included in the generation
f evidence-based medicine. Although many still think of
andomized controlled trials (RCTs) as synonymous with
vidence-based medicine, there is no question that evidence
hould go far beyond that brought by such trials. Popula-
ions included in RCTs are far from representative of the
opulations with a given disease seen in everyday practice.
ndeed, many exclusion criteria apply in RCTs ; in particular,
he presence of concomitant diseases or conditions such as
hronic renal failure result in the exclusion of important,
nd often more at risk, populations. In this regard, elderly
atients are often excluded, per protocol or de facto, from
CTs, so that it may be difﬁcult to determine whether the
onclusions drawn from these trials actually apply to elderly
opulations. Evidence must therefore be sought from other
ources, and well-designed registries probably provide the
est complementary source of data.
Many such unresolved clinical questions were thus tack-
ed using the FAST-MI data. In AMI, France has gathered
long-standing experience in the use of prehospital ther-
py, and prehospital ﬁbrinolysis has become the standard
f care, when this reperfusion method is chosen ; most of
he patients are sent for coronary angiography and PCI soon
fterwards. This pharmaco-invasive approach is quite dif-
erent from stand-alone ﬁbrinolysis, which has been shown
n RCTs to be clinically inferior to primary PCI. The results of
he pharmaco-invasive strategy used in France were there-
ore compared with the results of primary PCI [6].
Statistical methods can help to determine whether the
utcomes observed in a registry cohort as a whole are
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Pigure 1. Change over time in percentage of patients aged ≤
0 years in the three nationwide French registries (1995, 2000 and
005).
alid, and are not fraught with biases, in particular pres-
ription bias. Multivariable analysis, for example, adjusts
or known potential confounders. Another statistical tech-
ique is the propensity score, which involves the building
f a probability score for getting one type of treatment
ver another, according to the patient’s proﬁle ; the score
s then used to match one patient having actually received
ne type of treatment with another patient who received
he alternative treatment. In the case of the pharmaco-
nvasive approach to reperfusion, two cohorts were built,
ach comprising 448 patients, with the same likelihood of
eceiving either type of reperfusion therapy, and conse-
uently having similar baseline characteristics (Table 1);
he clinical outcomes in these two groups were found to
e very similar (Fig. 2). Similar techniques can be used
o address a number of questions that are unresolved by
CTs. As the totality of medications used, whether cardio-
ascular or non-cardiovascular, was recorded in FAST-MI,
any issues could be examined. Thus, a strong inverse
orrelation was found between the early prescription ofigure 2. Similar death rates at 1 month and at 1 year in patients
reated with primary percutaneous coronary intervention or intra-
enous ﬁbrinolysis for ST-segment elevation myocardial infarction.
ropensity-score-matched cohorts.
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Table 1 Example of two populations matched on a propensity score : patients treated with primary PCI vs. patients
treated with intravenous ﬁbrinolysis.
Primary PCI (n = 448) Fibrinolysis (n = 448) P-value
Age (years; mean± SD) 60.9± 13.8 60.5± 12.8 0.68
GRACE risk score (in-hospital mortality) [11] 145± 34 144± 31 0.74
Female sex 110 (25) 95 (21) 0.23
Hypertension 196 (44) 181 (40) 0.31
Diabetes 67 (15) 60 (13) 0.50
Hyperlipidaemia 207 (46) 191 (43) 0.28
Current smoking 203 (45) 189 (42) 0.35
Family history 124 (28) 144 (32) 0.14
History of AMI 47 (10.5) 40 (9) 0.43
History of stroke 8 (2) 5 (1) 0.40
History of peripheral artery disease 16 (4) 19 (4) 0.60
History of heart failure 2 (0.4) 2 (0.4) 1.00
Chronic renal failure 9 (2) 8 (2) 0.81
Early treatment
Aspirin 417 (93) 416 (93) 0.90
Statin 371 (83) 375 (84) 0.72
Beta-blocker 349 (78) 351 (78) 0.87
ACE inhibitor or ARB 248 (55) 226 (50) 0.14
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AAMI: acute myocardial infarction; ACE-I: angiotensin-converting en
intervention.
patients on sulfonylureas before the AMI, comparing those
treated with glibenclamide, a medication known to block
the mechanisms of ischaemic preconditioning, with those
receiving the pancreatic-speciﬁc sulfonylureases gliclazide
or glimepiride; in-hospital mortality and complications were
more frequent in the patients on glibenclamide, a ﬁnding
which suggested a true protective role of ischaemic pre-
conditioning in patients developing AMI [8]. Recently, we
investigated the inﬂuence of the co-prescription of proton
pump inhibitors on clinical outcomes in patients treated
with clopidogrel, and found no deleterious effect on the
occurrence of ischaemic events [9]. Finally, the collection of
serum and DNA in a large proportion of the patients gave us
the opportunity to test new biological markers and to assess
the interactions of gene variants with the efﬁcacy of medica-
tions, opening a door into the ﬁeld of pharmaco-genetics; for
instance, in the FAST-MI population, patients with two vari-
ant alleles of the cytochrome CYP2C19, an enzymatic system
needed for the transformation of clopidogrel into its active
metabolite, were at higher risk of developing ischaemic
events, both at the acute stage and during follow-up, sug-
gesting a reduced efﬁcacy of clopidogrel in this subgroup of
patients [10].
A word of caution, however. Although observational
medicine can be extremely helpful, as described above, it
should nevertheless be kept in mind that it is subject to bias,
particularly when trying to assess the impact of different
medications or therapeutic strategies on outcomes. Though
some of the biases can be corrected by the use of appropri-
ate statistical techniques, unknown confounders may exist
that render any causal relationship questionable. Indeed,
registries can show correlations between parameters and
outcomes, but these associations do not necessarily reﬂect
a causal relationship. This certainly forms one of the major
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i; ARB: angiotensin-receptor blocker; PCI: percutaneous coronary
imitations in the use of observational data to assess the
fﬁcacy (and safety) of medications or procedures, and it
hould always be taken into consideration.
Finally, registries need the contribution of many clin-
cians and centres, and setting up a registry offers a
nique opportunity of collaborative work within a net-
ork of centres. In this regard, the FAST-MI experience has
een extremely positive, with over 220 centres involved,
nd many of the participating clinicians involved in the
riting and/or criticism of the papers or presentations gen-
rated. Currently, more than 100 different clinicians or
iologists have co-authored published abstracts or articles
rom FAST-MI. This positive collaborative experience has
reatly facilitated the launch of the FAST-MI 2010 registry,
hich is based on the same methods as FAST-MI: FAST-MI 2010
as included over 4000 patients, who will be followed for a
eriod of at least 5 years from now. This will give France the
nique opportunity to analyse the evolution of the charac-
eristics, management and outcomes of AMI patients, on a
ationwide scale, over a 15-year period.
Overall, the FAST-MI experience can lead the way to many
ther registries in our specialty, many of which are already
unning under the auspices of the French Society of Cardi-
logy and will without doubt bring results as noteworthy as
hose of FAST-MI.
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